DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: The safety of pranlukast and montelukast during the first trimester of pregnancy: A prospective, two‐centered cohort study in Japan

Journal Article · · Congenital Anomalies (1987)
DOI: https://doi.org/10.1111/cga.12471 · OSTI ID:1877307
ORCiD logo [1];  [2];  [1];  [1]; ORCiD logo [3];  [4];  [2];  [5];  [3];  [6];  [7];  [8];  [1]
  1. Department of Pharmacy Yamagata University Hospital Yamagata Japan
  2. The Japan Drug Information Institute in Pregnancy National Center for Child Health and Development Tokyo Japan
  3. Department of Obstetrics and Gynecology Yamagata University Faculty of Medicine Yamagata Japan
  4. Department of Obstetrics and Gynecology Yamagata Prefecture Central Hospital Yamagata Japan
  5. Department of Pharmacy Toranomon Hospital Tokyo Japan
  6. Department of Biostatistics, M&,D Data Science Center Tokyo Medical and Dental University Tokyo Japan
  7. Division of Medical Genetics National Center for Child Health and Development Tokyo Japan
  8. The Japan Drug Information Institute in Pregnancy National Center for Child Health and Development Tokyo Japan, Center of Maternal‐Fetal, Neonatal and Reproductive Medicine National Center for Child Health and Development Tokyo Japan

Abstract For leukotriene receptor antagonists (LTRAs), especially pranlukast, safety data during pregnancy is limited. Therefore, we conducted a prospective, two‐centered cohort study using data from teratogen information services in Japan to clarify the effects of LTRA exposure during pregnancy on maternal and fetal outcomes. Pregnant women who being counseled on drug use during pregnancy at two facilities were enrolled. The primary outcome of this study was major congenital anomalies. The incidence of major congenital anomalies in women exposed to montelukast or pranlukast during the first trimester of pregnancy was compared with that of controls. Logistic regression analysis was performed to analyze the effects of maternal LTRA use during the first trimester of pregnancy on major congenital anomalies. The outcomes of 231 pregnant women exposed to LTRAs (montelukast n  = 122; pranlukast n  = 106; both n  = 3) and 212 live births were compared with those of controls. The rate of major congenital anomalies in the LTRA group was 1.9%. Multivariable logistic regression analysis revealed that LTRA exposure was not a risk factor for major congenital anomalies (adjusted odds ratio, 0.78; 95% confidence interval, 0.23–2.05; p  = 0.653). In addition, no significant difference was detected in stillbirth, spontaneous abortion, preterm birth, and low birth weight between the two groups. The present study revealed that montelukast and pranlukast were not associated with the risk of major congenital anomalies. Our findings suggest that LTRAs could be safely employed for asthma therapy during pregnancy.

Sponsoring Organization:
USDOE
OSTI ID:
1877307
Journal Information:
Congenital Anomalies (1987), Journal Name: Congenital Anomalies (1987) Vol. 62 Journal Issue: 4; ISSN 0914-3505
Publisher:
Wiley-BlackwellCopyright Statement
Country of Publication:
Japan
Language:
English

References (18)

Japanese guidelines for allergic rhinitis 2020 journal July 2020
The risk of congenital malformations, perinatal mortality and neonatal hospitalisation among pregnant women with asthma: a systematic review and meta-analysis journal March 2013
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision journal October 2017
Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma journal June 1997
Fetal Exposure to Montelukast and Congenital Anomalies: A Population Based Study in Denmark: Montelukast and Congenital Anomalies journal March 2017
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*: ARIA: 2008 Update journal March 2008
Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes journal February 2006
The course of asthma during pregnancy, post partum, and with successive pregnancies: A prospective analysis journal March 1988
Allergic diseases and asthma in pregnancy, a secondary publication journal January 2017
Safety of leukotriene receptor antagonists in pregnancy journal March 2007
Effect of maternal asthma on birthweight and neonatal outcome in a British inner-city population journal March 2007
Pregnancy outcome after first trimester exposure to domperidone—An observational cohort study journal February 2021
Atypical Antipsychotic Drugs and Pregnancy Outcome: A Prospective, Cohort Study journal January 2013
Effects of asthma severity, exacerbations and oral corticosteroids on perinatal outcomes journal August 2012
Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications journal January 2012
Asthma during Pregnancy in a Population-Based Study - Pregnancy Complications and Adverse Perinatal Outcomes journal August 2014
Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes journal August 2009
Asthma Prevalence among Pregnant and Childbearing-aged Women in the United States: Estimates from National Health Surveys journal May 2003